Reduced-dose WBRT combined with SRS for 1–4 brain metastases aiming at minimizing neurocognitive function deterioration without compromising brain tumor control

Toshimichi Nakano, Hidefumi Aoyama, Shunsuke Onodera, Hiroshi Igaki, Yasuo Matsumoto, Ayae Kanemoto, Shigetoshi Shimamoto, Masayuki Matsuo, Hidekazu Tanaka, Natsuo Oya, Tomohiko Matsuyama, Atsushi Ohta, Katsuya Maruyama, Takahiro Tanaka, Nobutaka Kitamura, Kohei Akazawa, Katsuya Maebayashi, for the Japanese Radiation Oncology Study Group 13-1 (JROSG13-1) Investigators

**ARTICLE INFO**

**Keywords:**
- Brain metastases
- Cognition
- Recurrence
- Radiation
- Whole brain
- Stereotactic radiosurgery

**ABSTRACT**

**Background and purpose:** To minimize cognitive decline without increasing brain tumor recurrence (BTR) by reduced-dose whole-brain radiotherapy (RD-WBRT) (25 Gy, 10 fractions) + stereotactic radiosurgery (SRS) in patients with ≤ 4 brain metastases.

**Materials and methods:** Eligible patients with ≤ 4 brain metastases on contrast-enhanced MRI and Karnofsky Performance Status ≥ 70. The primary endpoint was the non-inferiority of BTR at distant sites in the brain (BTR-distant)-free survival at 6 months compared to that of the standard dose (SD)-WBRT (30 Gy, 10 fractions) + SRS arm in a randomized clinical trial (JROSG99-1) of SRS with/without SD-WBRT. Secondary endpoints included BTR at any brain sites (BTR-all) and neurocognitive function assessed by a six-test standardized battery.

**Results:** Forty patients from seven institutions were enrolled (median age 69 years). The primary tumor site was a lung in 28 patients; 20 patients had a solitary brain metastasis. The median survival time was 19.0 months (95% CI: 13.8%–27.5%). The BTR-distant-free survival at 6 months was 76.9% (95.5%–87.7%), which is comparable to that of historical control although predetermined non-inferiority (>71%) could not be confirmed (p = 0.16). The cumulative incidence of BTR-all at 6 months accounting for the competing risk of death was 23.0% (11.4%–37.1%), which was not worse than that of historical control (p = 0.774). The frequency of the cumulative incidence of persistent cognitive decline at 6 months was 48.6% under the [≥2.0 SD in ≥ 1 test] definition.

**Conclusions:** RD-WBRT may yield comparable intracranial tumor control when combined with SRS, and may reduce the risk of neurocognitive decline compared to that after SD-WBRT.

* Corresponding authors at: Department of Radiation Oncology, Hokkaido University Faculty of Medicine, North 15, West 7, Sapporo 060-8638, Japan
**E-mail addresses:** h-aoyama2019@med.hokudai.ac.jp (H. Aoyama), akazawa@med.niigata-u.ac.jp (K. Akazawa).
1 Equal contributions: Toshimichi Nakano and Hidefumi Aoyama made equal contributions to this work.
2 Statistical analysis author’s contact information: Prof. Kohei Akazawa, Department of Medical Informatics, Niigata University Medical and Dental Hospital, 1-754, Asahimachi-dori, Niigata 951-8520, Japan

https://doi.org/10.1016/j.ctro.2022.09.005

Received 20 July 2022; Received in revised form 19 September 2022; Accepted 22 September 2022
Available online 27 September 2022

2405-6308/© 2022 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Characteristics of the 40 patients at the patient and lesion levels

| Characteristics       | Patient level (N = 40) | Lesion level (N = 73) |
|-----------------------|------------------------|-----------------------|
| **Age, years**        | Mean (SD)              | Median                |
|                       | 68.3 (8.1)             | 69                    |
| **Range:**            | 18-59                  | 10-19 mm              |
|                       | ≥10 mm                 | ≥10 mm                |
|                       | 60-69                  | 20-30 mm              |
|                       | 70-80                  |                       |
| **Gender**            | Male                   | 22                    |
|                       | Female                 | 18                    |
| **Primary tumor**     | Lung, adenocarcinoma   | 24                    |
|                       | (EGFR or ALK positive) | (9)                   |
|                       | (EGFR or ALK negative) | (15)                  |
|                       | Lung, non-adenocarcinoma | 4                  |
|                       | (Squamous-cell carcinoma) | (2)               |
|                       | (Others)               | (2)                   |
|                       | Brain                  | 2                     |
|                       | Kidney                 | 2                     |
|                       | Bladder                | 4                     |
|                       | Ovary                  | 2                     |
| **KPS**               | 100                    | 15                    |
|                       | 90                     | 16                    |
|                       | 80                     | 5                     |
|                       | 70                     | 4                     |
| **Status of Primary cancer** | Controlled | 23                   |
|                       | Not-controlled         | 17                    |
| **Extracranial metastases** | Absent | 18                   |
|                       | Present                | 22                    |
| **Number of brain metastases** | 1                  | 21                    |
|                       | 2                      | 10                    |
|                       | 3                      | 5                     |
|                       | 4                      | 4                     |
| **DS-GPA**            | 0.0-1.0                | 2                     |
|                       | 1.5-2.0                | 11                    |
|                       | 2.5-3.0                | 19                    |
|                       | 3.5-4.0                | 8                     |
| **Neurologic symptom**| Symptomatic            | 16                    |
|                       | Asymptomatic           | 24                    |
| **Cognitive test score** | HVLTR total recall     | -1.27 (1.24)          |
|                       | HVLTR delay recall     | -1.49 (1.25)          |
|                       | HVLTR delay recognition| -0.76 (1.23)          |
|                       | TMT-A                  | -0.78 (1.42)          |
|                       | TMT-B                  | -1.31 (1.92)          |
|                       | COWA                   | -0.27 (1.14)          |
| **Size, maximum diameter (mm)** | Median | 11 mm                |
|                       | <10 mm                 | 27                    |
|                       | 10-19 mm               | 25                    |
|                       | 20-30 mm               | 21                    |
| **Radiation method**  | Single-fraction SRS    | 36                    |
|                       | Hypo-fractionated SRS  | 27                    |

Abbreviations: EGFR, Epidermal Growth Factor Receptor; ALK, Anaplastic Lymphoma Kinase; TKI, Tyrosine Kinase Inhibitor; KPS, Karnofsky Performance Status; DS-GPA, Disease-specific Graded Prognostic Assessment; HVLTR, Hopkins Verbal Learning Test Revised; TMT, Trail Making Test; COWA, Controlled Oral Word Association.

Introduction

Brain metastasis is the most common brain tumor, as it develops in 20% – 40% of patients with systemic cancers. The number of patients diagnosed with brain metastases has been constantly increasing, due in part to the improvement of systemic therapy and the increasing quality and prevalence of MRI in recent years. The standard treatment for brain metastases has been whole-brain radiation therapy (WBRT), but there has also been concern about the cognitive deterioration of patients as a result of the toxicity of WBRT. Treatment with stereotactic radiosurgery (SRS) without WBRT is thus becoming more widely used for patients whose number of brain metastases is limited to 3–4. However, the avoidance of WBRT results in a higher risk of brain tumor recurrence (BTR) at distant sites in the brain (BTR-distant) with or without BTR at local sites that received SRS (BTR-all). More importantly, the higher risk of BTR could translate to an impairment of overall survival in some subsets of patients. In addition, there remains large regions of the world where frequent monitoring by enhanced-MRI after SRS-alone or advanced forms of radiation therapy such as intensity modulated radiation therapy (IMRT) or stereotactic body radiosurgery (SRS) are not commonly available. The optimal use of WBRT thus remains to be determined.

The risk of developing one or more radiation-induced late adverse effects, including cognitive decline, is closely related to the total radiation dose and the dose-per-fraction. The current standard dose-fractionation regimens of WBRT, such as 30 Gy in 10 fractions, were established in the 1970s – 80s when MRI and stereotactic radiosurgery (SRS) were not commonly available, and the primary treatment goal of WBRT was its therapeutic effect on already visualized metastases rather than non-visualized micro-metastases. Today, both WBRT and SRS are readily available worldwide, and thus we considered that the role of WBRT could be limited to merely avoiding the progression of non-visualized micro-metastases or slightly enhancing the treatment effect for already visualized metastases (especially large metastases).

Reduced dose (RD)-WBRT, such as 25 Gy in 10 fractions, was used in the clinical trials examining the role of prophylactic cranial irradiation (PCI) for limited-stage small cell lung cancer (SCLC) or locally advanced non-small-cell lung cancer, and the incidence of cognitive decline in these scenarios is reported to be significantly lower than that by standard-dose WBRT (SD-WBRT). In addition, in a single-arm study conducted using 25 Gy/10 fractions in patients with SCLC, transient decreases were observed in executive function and language after PCI, but the decreases improved to the pretreatment levels in the long term.

We conducted the present non-randomized, single-arm study to determine whether the combination of RD-WBRT and SRS could be used to minimize the risk of cognitive decline without compromising the brain tumor control for patients with 1–4 brain metastases.

Patients and methods

Study design and patients

This was a multi-institutional phase II study by the Japanese Radiation Oncology Study Group (JROSG 13–1). Adult patients (20–80 years old) with 1–4 brain metastases, all of which were ≤ 3 cm in diameter, were eligible for the trial. The eligibility criteria also included a Karnofsky Performance Status (KPS) ≥ 70 and pathological confirmation of...
Table 2
Local tumor control of JROSG13-1 and JROSG99-1 according to the maximum tumor diameter

| Maximum diameter | Treatment | N  | Time point % (95 % CI) | p       |
|------------------|-----------|----|-----------------------|---------|
|                  |           |    | 6 months              | 12 months | 24 months |
| JROSG13-1 (present study) | All      | 72 | 96.9 (88.1-99.2)      | 86.7 (73.9-93.5) | 86.7 (73.9-93.5) | 0.009 |
| ≥15 mm           | RD-WBRT + SRS | 28 | 91.5 (70.0-97.8)      | 75.3 % (50.1-89.0) | 75.3 % (50.1-89.0) | 0.009 |
| <15 mm           | RD-WBRT + SRS | 44 | 100 %                 | 93.4 % (75.9-98.3) | 93.4 % (75.9-98.3) | 0.003 |
| ≥20 mm           | SD-WBRT + SRS | 21 | 88.2 (60.6-96.9)      | 67.9 % (38.9-85.3) | 67.9 % (38.9-85.3) | 0.003 |
| <20 mm           | RD-WBRT + SRS | 51 | 100 %                 | 94.2 % (78.5-98.5) | 94.2 % (78.5-98.5) | 0.003 |
| JROSG99-1 [2]    | All       | 205| 87.4 % (80.5-92.0)    | 80.2 % (71.3-86.6) | 71.0 % (58.4-80.4) | 0.004 |
| ≥15 mm           | All       | 90 | 91.1 % (79.8-96.2)    | 88.6 % (76.0-94.8) | 88.6 % (76.0-94.8) | 0.004 |
| <15 mm           | All       | 115| 84.8 % (74.9-91.0)    | 73.2 % (59.2-83.0) | 51.2 % (29.8-69.1) | 0.042 |
| ≥20 mm           | All       | 43 | 84.9 % (64.0-94.2)    | 79.2 % (56.0-91.1) | 79.2 % (56.0-91.1) | 0.042 |
| <20 mm           | All       | 50 | 83.0 % (62.2-92.9)    | 60.7 % (32.3-80.2) | 16.2 % (9.5-49.1) | 0.023 |
| JROSG99-1 [2]    | All       | 65 | 96.4 % (77.2-99.5)    | 96.4 % (77.2-99.5) | 96.4 % (77.2-99.5) | 0.023 |
| ≥20 mm           | All       | 30 | 90.5 % (66.7-97.6)    | 81.5 % (50.1-94.1) | 81.5 % (50.1-94.1) | 0.06 |
| <20 mm           | All       | 30 | 83.0 % (53.1-94.7)    | 59.8 % (23.3-84.3) | 19.9 % (1.0-56.7) | 0.13 |
| JROSG99-1 [2]    | All       | 60 | 91.9 % (76.9-97.3)    | 91.9 % (76.9-97.3) | 91.9 % (76.9-97.3) | 0.13 |

Abbreviations: RD-WBRT, reduced-dose whole brain radiation therapy; SD-WBRT, standard-dose whole brain radiation therapy; SRS, stereotactic radiosurgery

Table 3
Cumulative incidence of brain tumor recurrence (BTR) in the JROSG13-1, JROSG99-1 and N0574 trials

| Cumulative incidence | Treatment                      | 6 months | 12 months |
|----------------------|--------------------------------|----------|-----------|
| BTR-distant          | RD-WBRT + SRS (present study) | 20.5 %   | 28.2 %    |
|                     | SD-WBRT + SRS                  | 15.2 %   | 25.4 %    |
|                     | (JROSG99-1) [2]                | 25.5 %   | 37.0 %    |
|                     | SD-WBRT + SRS (N0574) [3]     | 5.3 %    | 7.5 %     |
|                     | SRS-alone (JROSG99-1) [2]     | 46.6 %   | 50.0 %    |
|                     | SRS-alone (N-0574) [3]        | 22.9 %   | 30.0 %    |
| BTR-all              | RD-WBRT + SRS (present study) | 23.0 %   | 30.7 %    |
|                     | SD-WBRT + SRS                  | 16.9 %   | 28.8 %    |
|                     | (JROSG99-1) [2]                | 27.5 %   | 40.6 %    |
|                     | SD-WBRT + SRS (N0574) [3]     | 11.6 %   | 15.0 %    |
|                     | SRS-alone (JROSG99-1) [2]     | 51.6 %   | 60.0 %    |
|                     | SRS-alone (N-0574) [3]        | 35.3 %   | 49.5 %    |

Abbreviations: RD-WBRT, reduced-dose whole-brain radiation therapy; SD-WBRT, standard-dose whole-brain radiation therapy; SRS, stereotactic radiosurgery

an extracranial tumor site. The exclusion criteria included a past history of surgery or radiation to the brain, the presence of metastasis to the brainstem or leptomeningeal dissemination, and inability to take cognitive function tests or quality of life (QOL) surveys. Brain metastases from small cell cancers, germ cell tumors, or lymphoma were also excluded. Each participating institution provided institutional review board approval, and each patient provided written informed consent. This trial is registered with the UMIN Clinical Trial Registry (UMIN000009055).

Procedure
The radiation dose of single-fraction SRS (SF-SRS) prescribed to the 95 % of the gross tumor volume defined as the enhanced area on MRI was 22–24 Gy for lesions < 2 cm and 18–22 Gy for lesions >2 cm. The use of hypo-fractionated SRS (HF-SRS), which has an effect that is biologically identical to that of various protocols of SF-SRS, such as 28–35 Gy in 4 fractions or 26–30 Gy in 3 fractions, was allowed. RD-WBRT (25 Gy in 10 fractions) was started within 1 week after the final date of the patient’s SRS.

End points
This study’s primary endpoint was the BTR-distant-free survival of patients at 6 months after the completion of radiation therapy. The secondary endpoints included overall survival (OS), local tumor control, cognitive functional change, radiation-related adverse effects, and the cause of death. The cumulative incidences of BTR-distant and BTR-all were estimated by the competing risk method to account for the competing risk of death. Gray’s test was used to test for significant differences in the cumulative incidence of BTR-distant and BTR-all.

Contrast-enhanced MRI was taken at baseline and 4, 6, 9, and 12 months and every 6 months thereafter. The quality-of-life measures included the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ-C30) and the Brain Cancer Module 20 (BN20).[5] All treatment-related toxicities and adverse events were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Sample size and statistical analyses
The target accrual was 40 patients with 33 as the number of occurred events. This target was calculated using the 95 % confidence interval (95 % CI) for an exponential model, based on having 80 % power to detect the non-inferiority of RD-WBRT combined with stereotactic radiosurgery (SRS) of JROSG13-1 compared to that of SD-WBRT (30 Gy in 10 fractions) in the JROSG99-1 study.[2] (a randomized clinical trial [RCT] between SRS + SD-WBRT and SRS alone) with a one-sided significance level of 0.05 assuming that the 6-month BTR-distant-free survival of the JROSG99-1 study was 81 %, and defining non-inferiority as the same 6-month disease-free survival of >71 %.[9] We performed a one-sided test for the non-inferiority of the JROSG13-1...
study by comparing the observed 6-month BTR-distant-free survival rate with a margin of 10 % (i.e., a null hypothesis that the hazard ratio of the JROSG13-1 study was ≥ 1.625). In addition, a comparison of BTR-distant-free survivals accounting for the entire follow-up period of patients in each study was also conducted as a reference.

The statistical analyses were performed with SAS software, ver. 9.4 (SAS Institute, Cary, NC) and EZR (a modified version of R commander). [10] The cumulative incidences of BTR-distant and BTR-all were estimated by the competing risk method to account for the competing risk of death, and the statistical difference derived from the results of the JROSG99-1 study was compared by Gray’s test. The OS and BTR results of the JROSG99-1 trial[2] were calculated from the date of the last day of treatment with tyrosine kinase inhibitors (TKIs) before and/or after completion of SRS-alone (median 7.1, 95 %CI: 5.5–8.7) (log-rank, p = 0.0004) (Fig. A1), even though significantly older patients were included in the present study than in the JROSG99-1 (Table A1). In univariate analyses, KPS (90-100 vs. 70-80, p = 0.034), age (<70 vs. ≥ 70, p = 0.019), and the diagnosis-specific graded prognostic assessment (DS-GPA) (3.5-4.0 vs. 2.5-3.0 vs. 0-2.0, p = 0.017) were associated with better OS. Patients with EGFR- or ALK-positive lung-adenocarcinoma showed a trend of better OS compared to those with other histopathologies (MST: 37.2 months vs. 14.6 months, p = 0.077) (Table A2).

Follow-up enhanced MRI was available in all but one of the 40 patients, and 72 of the 73 treated lesions were evaluable with enhanced MRI at least once. Local tumor progression was observed in 9 of 72 lesions among 7 patients. The 12-month local tumor control rate was 86.7 % (95 %CI: 73.9–93.5) overall. Larger tumor diameter (≥20 mm) was associated with a lower control rate compared to that of smaller tumor diameter (<19 mm): 67.9 % (95 %CI: 38.9–85.3) versus 94.2 % (95 %CI: 78.5–98.5) at 12 months, respectively (log-rank, p = 0.003) (Table 2, Fig. A3).

Regarding the primary endpoint, BTR-distant was observed in 12 patients. The BTR-distant-free survival at 6 months was 76.9 % (95 %CI: 59.5–87.7) (Fig. A3), and therefore predetermined non-inferiority (>71 %) could not be confirmed (p = 0.16). However, non-inferiority was observed in the test accounting for the entire follow-up period (p = 0.004).

The cumulative incidences of BTR-distant at 6 and 12 months were 20.5 % (95 %CI: 9.6–34.2) and 28.2 % (95 %CI: 15.3–42.7), respectively, and these values were comparable to those of the SD-WBRT arm of the JROSG 99-1, which were 15.2 % (95 %CI: 7.5–25.5) and 32.3 % (95 %CI: 20.9–44.4), respectively (p = 0.846) (Fig. A4, Table 3). The cumulative incidences of BTR-all at 6 and 12 months were 23.0 % (95 %CI: 11.4–37.1) and 30.7 % (95 %CI: 17.3–45.4), which were comparable to those of the SD-WBRT arm of the JROSG 99-1 study at 16.9 % (95 %CI: 8.7–27.5) and 28.8 % (95 %CI:18.0–40.6), respectively (p = 0.774) (Fig. 1b).

### Overall survival and brain tumor recurrence

The median survival time (MST) was 19.0 months (95 %CI: 13.8–27.5), which was significantly longer than that of the JROSG99-1 (median 7.1, 95 %CI: 5.5–8.7) (log-rank, p = 0.0004) (Fig. A1), even though significantly older patients were included in the present study than in the JROSG99-1 (Table A1).

The primary tumor site was a lung in 28 patients (70 %). All 9 patients with EGFR- or ALK-positive lung-adenocarcinoma received a treatment with tyrosine kinase inhibitors (TKIs) before and/or after brain radiation therapy.

SF-SRS, 4-fraction HF-SRS, and 3-fraction HF-SRS were used in 36, 29, and 8 lesions, respectively. HF-SRS rather than SF-SRS was significantly more often applied to large metastases (≥1.5 cm) than smaller ones: 85.7 % (24/28) vs. 28.8 % (13/45) (p = 0.000002). The median prescribed radiation doses of the SF-SRS, 4-fraction HF-SRS, and 3-fraction HF-SRS were 22 Gy (range 18–23.7), 32.0 Gy (20–34.2), and 29.4 Gy (25.1–29.8) respectively. The median follow-up time was 16.3 months (range 2.5–49.7).

---

**Fig. 1.** Cumulative incidence of BTR-distant in the present study (JROSG13-1) and the historical data (JROSG99-1)
Clinical and Translational Radiation Oncology 37 (2022) 116–129

Table 4

Neurocognitive decline rate in the present study and publications

| Trial name          | Treatment                        | Age (years) | Definition of decline | Time point (months) | Decline rate |
|---------------------|----------------------------------|-------------|-----------------------|---------------------|--------------|
| JROSG13-1 (present study) | RD-WBRT + SRS | Mean 68.3 (SD 8.1) Median 69 (range 43-80) | >1.0 SD in ≥1 test | 6 | 75.0 % |
| NCCTG N0574 [3]  | SD-WBRT + SRS | Mean 61.4 (SD 10.6) | >1.0 SD in ≥1 test | 3 | 91.7 % |
|                     | SRS-alone | Mean 59.8 (SD 10.4) | >1.0 SD in ≥1 test | 3 | 85.0 % |
| NCCTG N107C/CEC3 [11] | Surgery + SD-WBRT | Median 62 (IQR 54-68) | >1.0 SD in ≥1 test | 6 | 59.7 % |
|                     | Surgery + SRS | Median 61 (IQR 54-66) | >1.0 SD in ≥1 test | 6 | 63.5 % |
| RTOG 0614 [13]   | SD-WBRT + memantine | Median 60 (range 31-84) | >2.0 SD or RCI in ≥1 test | 6 | 52.1 % |
|                     | SD-WBRT + placebo | Median 59 (range 29-86) | >2.0 SD or RCI in ≥1 test | 6 | 50.0 % |
| NRG CC001 [14]   | SD-WBRT + memantine | Median 61 (range 20-88) | >RCI in ≥1 test | 6 | 14.8 % |
|                     | SD-HA-WBRT + memantine | Median 62 (range 27-91) | >RCI in ≥1 test | 6 | 27.8 % |
| SAKK 15/12 [12]  | RD-HA-WBRT | Median 62.5 (range 34-75) | >1.0 SE in ≥1 test | 6 | 65.8 % |

The incidences of cognitive decline in this study according to the different definitions of cognitive decline are summarized in Table 4, and we compared these values to the results of previous brain metastasis trials in which cognitive function after radiation was assessed by the same standardized cognitive battery.[8] The definitions of cognitive decline are not standardized and they differ among clinical trials; results should be carefully interpreted when they are compared with those of other trials, taking into account the definition of cognitive decline used. [11]

When we defined decline as [≥2.0 SD in ≥1 test] in the present study, the rate of decline was 48.6 % (Fig. 2). In the N0574 trial comparing SD-WBRT + SRS and SRS-alone,[3] the rates of decline were 72.9 % and 42.9 %, respectively. The decline rate in the present study was thus much lower than that in the SD-WBRT + SRS group in the N0574 trial, and it was close to that in the SRS-alone group.

When we used [≥1.0 SD in ≥1 test] as the definition of decline, the cognitive decline rate was 75.0 %. Similar definitions were used in the N107C/CEC3 trial (Surgery + SD-WBRT vs. Surgery + SRS),[12] the N0574 trial,[3] and the SAKK 15/12 trial (Hippocampal-avoidance [HA]-RD-WBRT).[13] The rates of cognitive decline in these studies were as follows: 85 % (N107C/CEC3) and 91.7 % (N0574) in the SD-WBRT group, 52 % (N107C/CEC3) and 63.5 % (N0574) in the SRS-alone group, and 65.8 % (SAKK15/12) in the HA-RD-WBRT group. Compared to those numbers, the decline rate in our present investigation is somewhere between SD-WBRT and the others. In addition, it is noteworthy that Vees et al. concluded in the SAKK15/12 trial that the rate of neurocognitive decline after HA-RD-WBRT was not significantly different from that of RD-WBRT.[13] However, it should be noted that the [≥1.0 SD in ≥1 test] criterion has high sensitivity but low specificity.[11]

When we used [≥2.0 SD or RCI (reliable change index) in ≥1 test] as the definition of cognitive decline, the decline rate was 59.7 % (Fig. A5). This definition was also used in the RTOG0614 trial (SD-WBRT + memantine vs. SD-WBRT + placebo).[14] The rate of cognitive decline in the present study was similar to the 64.9 % after SD-WBRT with placebo and 53.5 % after SD-WBRT with memantine in the RTOG0614 trial. In the NRG CC001 trial, the definition [≥RCI in ≥1 test] was used as the definition of cognitive decline, and the decline rate was 68.5 % after SD-WBRT + memantine and 59.5 % after HA-SD-WBRT + memantine.[15] The decline rate of 56.7 % in the present study...
seems similar to that after HA-SD-WBRT + memantine in the NRG CC001 trial. However, the decline rate in the present study under \([\geq 1.5\text{SD in } \geq 2 \text{ test}]\) was 42.6 %, which is higher than that after SRS-alone, i.e., 19.0 % (N0574) and 14.8 % (NCCTG N107C/CTC3). It would thus be reasonable to speculate that RD-WBRT could reduce the risk of cognitive decline compared to SD-WBRT. However, the risk of cognitive decline due to a toxic effect of WBRT remains.

In addition to the dose-fractionation schedule of WBRT, age is another factor that could strongly affect the rate of decline in patients’ cognitive function. The median age of the present patients was rather high at 69 years, and it was 6–9 years higher than the ages of the patients in the other studies cited herein (Table 4). It is quite likely that the ages of our patient population negatively influenced the cognitive preservation rate. In other words, it may be that the rate of cognitive decline after RD-WBRT would be lower than that after SD-WBRT, even though more elderly patients were registered in this study; this indicates the possibility of RD-WBRT as a new standard WBRT schedule for patients who are indicated for SRS from the viewpoint of the preservation of cognitive function.

As SRS becomes more and more widely adopted, and as new systemic therapies with some efficacy against brain metastases emerge, what are the indications for adding WBRT to SRS? As a patient’s prognosis improves, the significance of controlling brain tumors becomes more important in regard to OS as well as the maintenance of QOL.\[^4\] Apart from the reduction of BTR-distant, another important role of WBRT combined with SRS is to enhance the local tumor control compared to that provided by SRS alone. The results of all four of the randomized trials comparing SRS alone and SRS + WBRT demonstrated that not only the BTR-distant-free survival but also the local tumor control rate by SRS + WBRT was significantly higher than that by SRS alone.\[^2,3,16,17\] The significant benefit on local tumor control is especially prominent in medium-to-large tumors (\(\geq 15–20 \text{ mm}\)).\[^18,19\] In the above-mentioned JROSG99-1 trial, the local tumor control rates of lesions \(\geq 20 \text{ mm}\) at 12 months were 81.5 % after SD-WBRT + SRS and 59.8 % after SRS alone, and the discrepancy in the rates expanded further at 24 months to 81.5 % versus 19.9 % (Table 2). The use of hypofractionation might improve local tumor control to some extent compared to single-fraction SRS,\[^18,19\] but we observed that the combination of HF-SRS and RD-WBRT in the present study provided tumor control comparable to that of SD-WBRT + SRS for tumors < 20 mm and \(\geq 20 \text{ mm}\) at 12 months (94.2 % vs. 67.9 %), and more importantly, this effect was maintained for the next 12 months. The long-term tumor control observed in this study is especially relevant for patients who can expect a good prognosis (i.e., a median OS of 17 months as achieved in this study), in order to achieve long-term maintenance of QOL while avoiding neurologic death, despite the modest risk of neurocognitive decline. Therefore, RD-WBRT combined with HF-SRS might be particularly indicated for patients with favorable prognosis and harboring medium-to-large brain metastases, since medium-to-large brain metastases would be difficult to control by SRS with or without systemic therapies, or could be refractory to systemic therapies. RD-WBRT plus HF-SRS might also be appropriate for patients in whom frequent monitoring by enhanced-MRI after treatment with SRS alone would be difficult for financial or geometrical reasons.

**Study limitations**

Limitations of this study include the single-arm design and the small number of patients (\(n = 40\)); therefore, these data cannot be used to conclude the superiority of RD-WBRT + SRS over SRS with or without SD-WBRT in terms of avoiding BTR and the preservation of neurocognitive function. In addition, the effect of the use of TKIs was not negligible, though no significant difference was observed between patients who received TKI-therapy for EGFR/ALK-positive lung adenocarcinoma and the other patients in terms of either BTR-distant or BTR-all in the present study. Nonetheless, our findings are encouraging and
merit further investigation in one of the arms of a prospective randomized study designed to identify the optimal treatment for patients with a limited number of brain metastases.

**Conclusions**

By achieving durable brain tumor control, the combination of SRS and RD-WBRT may be an optimal treatment method for patients who are expected to have a good life expectancy and to maintain their QOL. The information obtained in this study will be important for physicians in regions of the world where the routine use of HA-WBRT and/or the administration of memantine for patients with brain metastases is not possible.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Data Availability Statement for this Work**

Research data are not available at this time.

**Acknowledgements**

The effort of Yukiko Morita and Mika Hasegawa, research assistants at the Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences; and of Miki Nagai and Kumiko Shirai of the Clinical and Translational Research Center, Niigata University Medical and Dental Hospital, Niigata, Japan should be acknowledged.

**Funding**

This work was partly supported by a grant from the Japan Society for the Promotion of Science KAKENHI program (no. 15H04903, 22H03008), a Health and Labor Sciences Research Grant (no. 19-EA1-010), and funds from the Niigata University Clinical Trial Support Project 2011.

**Previous presentation**

The 2020 Annual Meeting of the American Society for Radiation Oncology, Web, 2020

**Appendix A**

Figs. A1–A5.
Tables A1–A6.

**Fig. A1.** Overall survivals of the present study (JROSG13-1) and the historical data (JROSG99-1)
Fig. A2. Local tumor control according to maximum tumor diameter

Fig. A3. BTR-distant free survival of the present study (JROSG13-1) and the historical data (JROSG99-1)
Fig. A4. Cumulative incidence of BTR-all in the present study (JROSG13-1) and historical data (JROSG99-1)

Number at risk

| Treatment                  | Months | 0   | 6   | 12  | 18  | 24  | 30  | 36  | 42  | 48  | 54  | 60  |
|----------------------------|--------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| RD-WBRT + SRS (JROSG13-1) |        | 39  | 28  | 17  | 9   | 8   | 6   | 3   | 2   | 0   | 0   | 0   |
| SD-WBRT + SRS (JROSG99-1) |        | 59  | 26  | 14  | 11  | 9   | 6   | 5   | 4   | 2   | 2   | 0   |
| SRS-alone (JROSG99-1)     |        | 60  | 15  | 6   | 2   | 1   | 1   | 1   | 1   | 0   | 0   | 0   |

Fig. A5. Cumulative incidence of persistent neurocognitive decline defined as “>2.0 SD or RCI in ≥ 1 test”
Table A1
Characteristics of the patients in the present study (JROSG13-1) and the historical data (JROSG99-1)

| Characteristics                         | JROSG13-1 (N = 40) | JROSG99-1 (N = 132) | P       |
|-----------------------------------------|---------------------|---------------------|---------|
| Age, years                              | 68.3 (8.1)          | 62.3 (11.1)         | 0.0013  |
| Gender                                  | male/Female         | 99/33               | 0.0153  |
| Primary tumor site                      | lung/Others         | 88/44               | 0.6935  |
| KPS                                     | 90-100/70-80        | 78/54               | 0.0343  |
| Status of primary site                  | controlled/uncontrolled | 69/63           | 0.5615  |
| Extracranial mets.                      | absent/present      | 54/78               | 0.6459  |
| Number of brain mets.                   | 1/≥2                | 65/66               | 0.7497  |

Table A2
Overall survival, univariate analysis

| Factors                           | N  | MST, months | 95 % CI | p     |
|------------------------------------|----|-------------|---------|-------|
| KPS                                |    |             |         |       |
| 70-80                              | 9  | 10.0        | 2.5-NA  | 0.034 |
| 90-100                             | 31 | 19.9        | 14.2-33.7|       |
| Age                                |    |             |         |       |
| ≥70                                | 18 | 14.2        | 10-19.9 | 0.019 |
| <70                                | 22 | 33.7        | 11.4-NA |       |
| Extracranial Metastases            |    |             |         |       |
| Absent                             | 18 | 22.9        | 12.2-NA | 0.194 |
| Present                            | 22 | 14.2        | 7.7-20.3|       |
| Primary cancer status              |    |             |         |       |
| Controlled                         | 23 | 17.9        | 11.4-47.2| 0.725 |
| Uncontrolled                       | 17 | 19.9        | 7.7-27.5 |       |
| DS-GPA                             |    |             |         |       |
| 0-2.0                              | 13 | 10.0        | 5.1-20.3| 0.017 |
| 2.5-3.0                            | 19 | 19.0        | 11.4-47.2|       |
| 3.5-4.0                            | 8  | 37.2        | 14.2-NA |       |
| Histopathology                     |    |             |         |       |
| EGFR or ALK positive lung-adenocarcinoma* | 9  | 37.2        | 11.2-NA | 0.077 |
| Others                             | 31 | 14.6        | 10.3-22.9|       |
| Number of brain mets               |    |             |         |       |
| 1                                  | 21 | 19.0        | 10.3-33.7| 0.414 |
| 2-4                                | 19 | 19.3        | 11.2-37.2|       |
| Sum of tumor volume                |    |             |         |       |
| <5 cc                              | 26 | 20.3        | 14.2-47.2| 0.060 |
| ≥5 cc                              | 14 | 13.9        | 5.1-19.9 |       |
| Max diameter of largest met         |    |             |         |       |
| <10 mm                             | 9  | 19.7        | 2.8-NA  | 0.734 |
| 10-19 mm                           | 11 | 17.9        | 10.3-NA |       |
| ≥20 mm                             | 20 | 17.0        | 7.7-33.7|       |

Abbreviations: EGFR, Epidermal Growth Factor Receptor; ALK, Anaplastic Lymphoma Kinase; TKI, Tyrosine Kinase Inhibitor; KPS, Karnofsky Performance Status; DS-GPA, Disease-specific Graded Prognostic Assessment.

* All patients with EGFR or ALK positive lung-adenocarcinoma received Tyrosine Kinase Inhibitor (TKI) treatment.
### Table A3
Cumulative incidence of BTR-distant, univariate analysis

| Factors                        | N   | 6 months (95% CI)         | 12 months (95% CI)          | p     |
|--------------------------------|-----|---------------------------|-----------------------------|-------|
| Extracranial Metastases        |     |                           |                             |       |
| Absent                         | 18  | 11.1 (1.9-29.8)           | 16.6 (4.1-36.5)             | 0.080 |
| Present                        | 21  | 28.5 (11.7-48.2)          | 38.0 (18.3-57.8)            |       |
| Primary cancer status          |     |                           |                             |       |
| Controlled                     | 22  | 18.1 (5.7-36.3)           | 22.7 (8.3-41.4)             | 0.280 |
| Uncontrolled                   | 17  | 23.5 (7.3-44.9)           | 35.2 (14.5-57.0)            |       |
| Histopathology                 |     |                           |                             |       |
| EGFR or ALK positive lung-adenocarcinoma* | 9  | 0                          | 11.1 (0.6-38.8)             | 0.138 |
| Others                         | 30  | 26.6 (12.6-43.0)          | 33.3 (17.5-50.0)            |       |
| Sum of tumor volume            |     |                           |                             |       |
| <5 cc                          | 25  | 16.0 (5.0-32.5)           | 24.0 (9.8-41.7)             | 0.583 |
| ≥5 cc                          | 14  | 28.5 (8.8-52.4)           | 35.7 (13.0-59.4)            |       |
| Max diameter of largest met    |     |                           |                             |       |
| <19 mm                         | 19  | 15.7 (3.9-34.9)           | 26.3 (9.6-46.8)             | 0.566 |
| ≥20 mm                         | 20  | 25.0 (9.1-44.9)           | 30.0 (12.3-50.1)            |       |
| No. of brain mets              |     |                           |                             |       |
| 1                              | 20  | 20.0 (6.2-39.3)           | 25.0 (9.1-44.9)             | 0.871 |
| 2-4                            | 19  | 21.0 (6.6-41.0)           | 31.5 (12.9-52.2)            |       |

Abbreviations: EGFR, Epidermal Growth Factor Receptor; ALK, Anaplastic Lymphoma Kinase.
* All patients with EGFR or ALK positive lung-adenocarcinoma received Tyrosine Kinase Inhibitor (TKI) treatment.

### Table A4
Cumulative incidence of BTR-all, univariate analysis

| Factors                        | N   | 6 months (95% CI)         | 12 months (95% CI)          | p     |
|--------------------------------|-----|---------------------------|-----------------------------|-------|
| Extracranial Metastases        |     |                           |                             |       |
| Absent                         | 18  | 11.1 (1.9-29.8)           | 16.6 (4.1-36.5)             | 0.040 |
| Present                        | 21  | 33.3 (14.9-53.1)          | 42.8 (21.9-62.3)            |       |
| Primary cancer status          |     |                           |                             |       |
| Controlled                     | 22  | 18.1 (5.7-36.3)           | 22.7 (8.3-41.4)             | 0.312 |
| Uncontrolled                   | 17  | 29.4 (10.7-51.1)          | 41.1 (18.6-62.6)            |       |
| Histopathology                 |     |                           |                             |       |
| EGFR or ALK positive lung-adenocarcinoma* | 9  | 0                          | 11.1 (0.6-38.8)             | 0.142 |
| Others                         | 30  | 30.0 (15.0-46.6)          | 36.6 (20.1-53.4)            |       |
| Sum of tumor volume            |     |                           |                             |       |
| <5 cc                          | 25  | 16.0 (5.0-32.5)           | 24.0 (9.8-41.7)             | 0.257 |
| ≥5 cc                          | 14  | 35.7 (13.0-59.4)          | 42.8 (17.7-66.0)            |       |
| Max diameter of largest met    |     |                           |                             |       |
| <19 mm                         | 19  | 15.7 (3.9-34.9)           | 26.3 (9.6-46.8)             | 0.362 |
| ≥20 mm                         | 20  | 35.0 (12.3-50.1)          | 35.0 (15.7-55.2)            |       |
| No. of brain mets              |     |                           |                             |       |
| 1                              | 20  | 25.0 (9.1-44.9)           | 30.0 (12.3-50.1)            | 0.808 |
| 2-4                            | 19  | 21.0 (6.6-41.0)           | 31.5 (12.9-52.2)            |       |

Abbreviations: EGFR, Epidermal Growth Factor Receptor; ALK, Anaplastic Lymphoma Kinase.
* All patients with EGFR or ALK positive lung-adenocarcinoma received Tyrosine Kinase Inhibitor (TKI) treatment.
Table A5
Quality of life at baseline and after radiation therapy

| No. of patients | BL 40 | 4 mo. 34 | 8 mo. 26 | 12 mo. 18 | BL vs. 4 mo., p | BL vs. 8 mo., p | BL vs. 12 mo., p |
|-----------------|-------|---------|---------|---------|-----------------|-----------------|------------------|
| QLQ-C30 | | | | | | | |
| Global health status/QOL* | Mean | 52.1 | 56.6 | 51.9 | 60.6 | 0.424 | 0.979 | 0.226 |
| SD | 25.6 | 22.5 | 22.0 | 22.3 | | | |
| Functional scales* | | | | | | | |
| Physical functioning (PF) | Mean | 77.5 | 72.2 | 69.2 | 70.0 | 0.186 | 0.142 | 0.287 |
| SD | 20.4 | 25.0 | 24.5 | 32.1 | | | |
| Role functioning (RF) | Mean | 72.1 | 72.2 | 77.3 | 72.2 | 0.985 | 0.491 | 0.988 |
| SD | 31.4 | 31.1 | 26.7 | 34.3 | | | |
| Emotional functioning (EF) | Mean | 75.0 | 84.8 | 83.0 | 82.9 | | 0.010 | 0.062 | 0.126 |
| SD | 17.4 | 14.0 | 15.7 | 18.8 | | | |
| Cognitive functioning (CF) | Mean | 69.6 | 68.6 | 69.2 | 68.5 | 0.841 | 0.948 | 0.862 |
| SD | 18.8 | 22.0 | 24.8 | 26.7 | | | |
| Social functioning (SF) | Mean | 72.9 | 81.9 | 84.6 | 71.3 | 0.074 | | 0.033 | 0.829 |
| SD | 23.5 | 18.1 | 17.6 | 31.7 | | | |
| Symptom scales** | | | | | | | |
| Fatigue (FA) | Mean | 35.8 | 35.9 | 37.6 | 34.0 | 0.980 | | 0.732 | 0.746 |
| SD | 21.1 | 17.7 | 19.4 | 18.5 | | | |
| Nausea and vomiting (NV) | Mean | 3.8 | 5.4 | 8.7 | 4.6 | 0.531 | | 0.294 | 0.734 |
| SD | 8.0 | 14.0 | 22.1 | 11.2 | | | |
| Pain (PA) | Mean | 27.9 | 17.6 | 25.0 | 26.9 | 0.070 | | 0.661 | 0.895 |
| SD | 28.1 | 17.9 | 23.2 | 28.7 | | | |
| Dyspnea (DY) | Mean | 25.0 | 25.5 | 21.8 | 22.2 | 0.943 | | 0.645 | 0.734 |
| SD | 30.0 | 28.5 | 23.0 | 25.6 | | | |
| Insomnia (SL) | Mean | 25.8 | 18.6 | 23.1 | 22.2 | 0.199 | | 0.674 | 0.640 |
| SD | 28.7 | 18.7 | 20.6 | 22.9 | | | |
| Appetite loss (AP) | Mean | 25.0 | 28.3 | 33.3 | 22.2 | 0.632 | | 0.273 | 0.751 |
| SD | 31.8 | 25.2 | 25.5 | 28.0 | | | |
| Constipation (CO) | Mean | 24.2 | 32.4 | 15.4 | 9.3 | 0.271 | | 0.193 | 0.053 |
| SD | 28.2 | 35.3 | 23.5 | 22.3 | | | |
| Diarrhea (DI) | Mean | 10.8 | 16.7 | 16.7 | 13.0 | 0.259 | | 0.366 | 0.756 |
| SD | 21.9 | 22.1 | 30.2 | 28.3 | | | |
| Financial difficulties (FI) | Mean | 29.2 | 19.6 | 16.7 | 20.4 | 0.139 | | 0.054 | 0.268 |
| SD | 27.4 | 27.4 | 21.6 | 28.3 | | | |
| QLQ-BN20 | | | | | | | |
| Symptom scales** | | | | | | | |
| Future uncertainty (BNFU) | Mean | 16.7 | 13.4 | 13.5 | 13.7 | 0.174 | | 0.227 | 0.369 |
| SD | 11.3 | 9.1 | 8.9 | 12.6 | | | |
| Visual disorder (BNVD) | Mean | 6.9 | 6.2 | 9.4 | 6.2 | 0.702 | | 0.382 | 0.756 |
| SD | 8.6 | 7.7 | 12.3 | 8.9 | | | |
| Motor dysfunction (BNMD) | Mean | 8.1 | 7.0 | 8.5 | 7.7 | 0.629 | | 0.834 | 0.898 |
| SD | 9.2 | 8.9 | 9.3 | 9.4 | | | |
| Communication deficit (BNCD) | Mean | 10.2 | 10.1 | 10.7 | 10.5 | 0.953 | | 0.875 | 0.948 |
| SD | 10.9 | 10.2 | 9.0 | 13.5 | | | |

(continued on next page)
| Table A5 (continued) | No. of patients | BL 4 mo. | 8 mo. | 12 mo. | BL vs. 4 mo., p | BL vs. 8 mo., p | BL vs. 12 mo., p |
|----------------------|----------------|----------|-------|--------|----------------|----------------|-----------------|
|                      |                | 40       | 34    | 26     | 18             |
| Headaches (BNHA)     | Mean           | 7.9      | 7.4   | 8.3    | 8.3            | 0.839           | 0.893           | 0.905           |
|                      | SD             | 11.9     | 11.7  | 12.7   | 13.1           |                |                 |                |
| Seizure (BNSE)       | Mean           | 2.5      | 1.5   | 1.3    | 0.9            | 0.476           | 0.441           | 0.315           |
|                      | SD             | 6.0      | 6.3   | 6.5    | 3.9            |                |                 |                |
| Drowsiness (BNDR)    | Mean           | 15.0     | 17.2  | 20.5   | 18.5           | 0.412           | 0.060           | 0.403           |
|                      | SD             | 10.5     | 12.0  | 12.7   | 16.1           |                |                 |                |
| Hair loss (BNHL)     | Mean           | 5.8      | 15.2  | 5.1    | 5.6            | 0.008           | 0.788           | 0.933           |
|                      | SD             | 11.0     | 17.1  | 9.2    | 12.8           |                |                 |                |
| Itchy skin (BNIS)    | Mean           | 10.0     | 9.3   | 7.1    | 11.1           | 0.842           | 0.439           | 0.808           |
|                      | SD             | 16.4     | 12.4  | 12.6   | 15.1           |                |                 |                |
| Weakness of leg (BNWL)| Mean           | 15.8     | 20.6  | 19.9   | 21.3           | 0.199           | 0.307           | 0.242           |
|                      | SD             | 16.4     | 14.8  | 14.2   | 16.0           |                |                 |                |
| Bladder control (BNBC)| Mean           | 7.9      | 7.4   | 10.3   | 8.3            | 0.804           | 0.347           | 0.885           |
|                      | SD             | 9.2      | 10.2  | 10.6   | 11.8           |                |                 |                |

* Scores range from 0 to 100, with a higher score representing a higher level of functioning or health status.
** Scores range from 0 to 100, with a higher score representing a higher degree of symptoms.

| Table A6 | Number of patients with an Adverse Event by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Definitely or Probably Related to the Protocol Treatment |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Toxocities | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 |
| Ear and labyrinth disorders | | | | | |
| External ear inflammation | 1 | 0 | 0 | 0 | 0 |
| Hearing impaired | 1 | 0 | 0 | 0 | 0 |
| Middle ear inflammation | 1 | 0 | 0 | 0 | 0 |
| Gastrointestinal disorders | | | | | |
| Nausea | 2 | 0 | 0 | 0 | 0 |
| General disorders and administration site conditions | | | | | |
| Gait disturbance | 0 | 1 | 0 | 0 | 0 |
| Malaise | 0 | 1 | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | | | |
| Anorexia | 2 | 1 | 0 | 0 | 0 |
| Nervous system disorders | | | | | |
| Central nervous system necrosis | 3 | 2 | 1 | 0 | 0 |
| Cognitive disturbance | 2 | 2 | 1 | 0 | 0 |
| Headache | 2 | 0 | 0 | 0 | 0 |
| Leukoencephalopathy | 5 | 2 | 1 | 1 | 0 |
| Somnolence | 0 | 1 | 0 | 0 | 0 |
| Psychiatric disorders | | | | | |
| Depression | 1 | 0 | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | | | |
| Alopecia | 1 | 5 | 0 | 0 | 0 |
| Maximum toxicity per person | 11 (27.5 %) | 10 (25 %) | 2 (5 %) | 1 (2.5 %) | 0 |

References

[1] Sperduto PW, Meeso S, Li J, Cagney D, Aizer A, Lin NU, et al. Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol 2020;38(32):3773–84.

[2] Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295 (21):2483.

[3] Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA 2016;316(4):491.

[4] Aoyama H, Tago M, Shirato H. Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1
Randomized Clinical Trial, JAMA Oncol 2015;1:457–64. https://doi.org/10.1001/jamaoncol.2015.1145.

Wolffon AH, Bae K, Komaki R, Meyers C, Movsas B, Le Pechoux C, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;81(1):77–84.

Li N, Zeng ZF, Wang SY, et al. Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA-N2 non-small-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy. Ann Oncol 2015;26:504–9. https://doi.org/10.1093/annonc/mdu567.

[7] Grosshans DR, Meyers CA, Allen PK, et al. Neurocognitive function in patients with small cell lung cancer: effect of prophylactic cranial irradiation. Cancer 2008;112:589–95. https://doi.org/10.1002/cncr.23522.

[8] Lin NU, Wefel JS, Lee EQ, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol 2013;14:e407–16. 2013. https://doi.org/10.1016/S1470-2045(13)70132-8.

[9] Marchin D, Cheung YB, Parmar MKB: in Marchin D, Cheung YB, Parmar MKB (eds): Survival analysis; a practical approach (ed 2). Chichester, England, John Wiley & Sons Ltd., 2006, pp 91-119.

[10] Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone marrow transplantation 48:452-8, 2013.10.1038/bmt.2012.244.

[11] Nakano T, Aoyama H, Saito H, et al: The neurocognitive function change criteria after whole-brain radiotherapy for brain metastasis, in reference to health-related quality of life changes: a prospective observation study. BMC Cancer 20:66, 2020.http://doi.org/10.1186/s12885-020-6559-3.

[12] Brown PD, Hallman KV, Gerhah JH, et al: Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCTCT N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049-1060, 2017.10.1016/S1470-2045(17)30441-2.

[13] Vees H, Caparrotti F, E bouet El, et al: Impact of Early Prophylactic Cranial Irradiation With Hippocampal Avoidance on Neurocognitive Function in Patients With Limited Disease Small Cell Lung Cancer. A Multicenter Phase 2 Trial (SAKK 15/12). Int J Radiat Oncol Biol Phys 107:279-287, 2020.10.1016/j.ijrobp.2020.02.029.

[14] Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 2015;17(14):1-10. https://doi.org/10.1093/neuonc/nox114.

[15] Brown PD, Gondi V, Pugh S, et al: Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol 38:1019-1029, 2020.10.1200/JCO.19.02767.

[16] Kocher M, Soffietti R, Abacioglu U, et al: Adjunctive whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29:134-41, 2011.10.1200/JCO.2010.30.1655.

[17] Chang EL, Wefel JS, Hess KR, et al: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomized controlled trial. Lancet Oncol 10:1037-44, 2009.10.1016/S1470-2045(09)70263-3.

[18] Minniti G, Scaringi C, Paolini S, et al: Single-Fraction Versus Multifraction (3 x 9 Gy) Stereotactic Radiosurgery for Large (>2 cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis. Int J Radiat Oncol Biol Phys 95:1142-8, 2016.10.1016/j.ijrobp.2016.03.013.

[19] Aoyama H, Shirato H, Onimaru R, et al: Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull. Int J Radiat Oncol Biol Phys 56:793-800, 2002.10.1016/s0360-3016(03)00014-2.